ANDREA BARTHOLOMEW: Open Payments
NPI 1609572221 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$809 in 43 payments from 19 companies in 2025. Trend: 2023 $499 · 2024 $847 · 2025 $809
Food & beverage: $810
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $121 |
| ABBVIE INC. | 5 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $89 |
| Exact Sciences Corporation | 5 | $85 |
| Novo Nordisk Inc | 3 | $49 |
| SANOFI-AVENTIS U.S. LLC | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Baxter Healthcare | 1 | $26 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Cologuard Collection Kit, TZIELD, Veozah, Wegovy, MOUNJARO.
Industry payments across UT — which companies pay providers there.
